公开(公告)号：EP2918603B1

公开(公告)日：2018-08-29

申请号：EP13853637.0

申请日：2013-11-08

申请人： University of Miyazaki ,  Perseus Proteomics Inc.

发明人： KUROSAWA, Yoshikazu ,  MORISHITA, Kazuhiro ,  ZHANG, Lilin ,  KUROSAWA, Gene ,  MITOMO, Katsuyuki ,  SUDO, Yukio ,  NOMURA, Fumiko ,  UKAI, Yoshinori

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  A61P35/02 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12P21/08

CPC分类号： C07K16/2881 ,  A61K2039/505 ,  C07K16/30 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/92

摘要： The present invention provides an antibody, in which the heavy chain first complementarity determining region (VH CDR1), the heavy chain second complementarity determining region (VH CDR2), and the heavy chain third complementarity determining region (VH CDR3) are shown in SEQ ID NOs: 1,2, and 7, respectively, and the light chain first complementarity determining region (VL CDR1), the light chain second complementarity determining region (VL CDR2), and the light chain third complementarity determining region (VL CDR3) are shown in SEQ ID NOs: 4, 5, and 6, respectively.

公开(公告)号：EP2708560A1

公开(公告)日：2014-03-19

申请号：EP12781761.7

申请日：2012-05-07

申请人： Perseus Proteomics Inc. ,  University of Miyazaki

发明人： KUROSAWA, Yoshikazu ,  MORISHITA, Kazuhiro ,  ZHANG, Lilin ,  KUROSAWA, Gene ,  MITOMO, Katsuyuki ,  SUDO, Yukio ,  NOMURA, Fumiko ,  UKAI, Yoshinori

IPC分类号： C07K16/30 ,  A61K39/395 ,  A61P35/02 ,  C12N15/09 ,  C12P21/08

CPC分类号： C07K16/30 ,  C07K16/2881

摘要： An object of present invention is to provide a complete human anti-human TfR antibody, which specifically recognizes human TfR, inhibits the survival or growth of cancer cells that highly express TfR, and has no immunogenicity to humans. The present invention provides an antibody which specifically reacts with human TfR, wherein the antibody comprises any one of the amino acid sequences shown in SEQ ID NOS: 1-3, 7-9, 13-15, 19-21, 25-27, 31-33, 37-39, 43-45, 49-51, 55-57, 61-63, 67-69, 73-75, 79-81, 85-87, 91-93, 97-99, 103-105, 109-111, and 115-117, as each of a heavy chain first complementarity determining region (VH CDR1), a heavy chain second complementarity determining region (VH CDR2), and a heavy chain third complementarity determining region (VH CDR3).

摘要翻译： 本发明的目的是提供一种完全人抗TfR抗体，其特异性识别人TfR，抑制高表达TfR的癌细胞的存活或生长，并且对人类没有免疫原性。 本发明提供与人TfR特异性反应的抗体，其中抗体包含SEQ ID NO： 31-33,37-39,43-45,49-51,55-57,61-63,67-69,73-75,77-81,85-87,91-93,97-99,103- 105，109-111和115-117，作为重链第一互补决定区（VH CDR1），重链第二互补决定区（VH CDR2）和重链第三互补决定区（VH CDR3） 。

公开(公告)号：EP2918603A1

公开(公告)日：2015-09-16

申请号：EP13853637.0

申请日：2013-11-08

申请人： University of Miyazaki ,  Perseus Proteomics Inc.

发明人： KUROSAWA, Yoshikazu ,  MORISHITA, Kazuhiro ,  ZHANG, Lilin ,  KUROSAWA, Gene ,  MITOMO, Katsuyuki ,  SUDO, Yukio ,  NOMURA, Fumiko ,  UKAI, Yoshinori

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  A61P35/02 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12P21/08

CPC分类号： C07K16/2881 ,  A61K2039/505 ,  C07K16/30 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/92

摘要： The present invention provides an antibody, in which the heavy chain first complementarity determining region (VH CDR1), the heavy chain second complementarity determining region (VH CDR2), and the heavy chain third complementarity determining region (VH CDR3) are shown in SEQ ID NOs: 1,2, and 7, respectively, and the light chain first complementarity determining region (VL CDR1), the light chain second complementarity determining region (VL CDR2), and the light chain third complementarity determining region (VL CDR3) are shown in SEQ ID NOs: 4, 5, and 6, respectively.

摘要翻译： 本发明提供一种抗体，其中重链第一互补决定区（VH CDR1），重链第二互补决定区（VH CDR2）和重链第三互补决定区（VH CDR3）在SEQ ID NOS：1,2和7，分别示出轻链第一互补决定区（VL CDR1），轻链第二互补决定区（VL CDR2）和轻链第三互补决定区（VL CDR3） 分别为SEQ ID NO：4,5和6。

公开(公告)号：EP2634194B1

公开(公告)日：2018-08-15

申请号：EP11836461.1

申请日：2011-10-28

申请人： Perseus Proteomics Inc.

发明人： ISHII, Keisuke ,  KATSUMI, Keiko ,  MATSUURA, Tadashi ,  SUDO, Yukio ,  MITOMO, Katsuyuki ,  KOUDA, Katsushi

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  C07K16/46 ,  C12N5/10 ,  C12N15/02 ,  C12P21/08

CPC分类号： C07K16/18 ,  A61K47/6849 ,  A61K2039/505 ,  C07K16/2896 ,  C07K2317/77

摘要： It is an object of the present invention to provide an anti-cadherin antibody having a high internalization capacity and provide an anti-cadherin antibody-drug conjugate that effectively kills cadherin-expressing cancer cells with the use of such antibody. The present invention provides an anti-cadherin antibody which recognizes a cadherin domain 1 (EC1) of cadherin and exhibits a high internalization capacity.

公开(公告)号：EP2634194A1

公开(公告)日：2013-09-04

申请号：EP11836461.1

申请日：2011-10-28

申请人： Perseus Proteomics Inc.

发明人： ISHII, Keisuke ,  KATSUMI, Keiko ,  MATSUURA, Tadashi ,  SUDO, Yukio ,  MITOMO, Katsuyuki ,  KOUDA, Katsushi

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  C07K16/46 ,  C12N5/10 ,  C12N15/02 ,  C12P21/08

CPC分类号： C07K16/18 ,  A61K47/48561 ,  A61K47/6849 ,  A61K2039/505 ,  C07K16/2896 ,  C07K2317/77

摘要： It is an object of the present invention to provide an anti-cadherin antibody having a high internalization capacity and provide an anti-cadherin antibody-drug conjugate that effectively kills cadherin-expressing cancer cells with the use of such antibody. The present invention provides an anti-cadherin antibody which recognizes a cadherin domain 1 (EC1) of cadherin and exhibits a high internalization capacity.

摘要翻译： 本发明的目的是提供具有高内化能力的抗钙粘蛋白抗体，并提供使用这种抗体有效杀死表达cadherin的癌细胞的抗钙粘蛋白抗体 - 药物偶联物。 本发明提供一种识别钙粘蛋白的钙粘蛋白结构域1（EC1）并显示高内在能力的抗钙粘蛋白抗体。

公开(公告)号：EP2634194A9

公开(公告)日：2014-04-02

申请号：EP11836461.1

申请日：2011-10-28

申请人： Perseus Proteomics Inc.

发明人： ISHII, Keisuke ,  KATSUMI, Keiko ,  MATSUURA, Tadashi ,  SUDO, Yukio ,  MITOMO, Katsuyuki ,  KOUDA, Katsushi

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  C07K16/46 ,  C12N5/10 ,  C12N15/02 ,  C12P21/08

CPC分类号： C07K16/18 ,  A61K47/48561 ,  A61K47/6849 ,  A61K2039/505 ,  C07K16/2896 ,  C07K2317/77

摘要： It is an object of the present invention to provide an anti-cadherin antibody having a high internalization capacity and provide an anti-cadherin antibody-drug conjugate that effectively kills cadherin-expressing cancer cells with the use of such antibody. The present invention provides an anti-cadherin antibody which recognizes a cadherin domain 1 (EC1) of cadherin and exhibits a high internalization capacity.